| Metric | Current Period | Prior Period | YoY |
|---|---|---|---|
| Revenue | ¥3217.5B | ¥2884.6B | +11.5% |
| Operating Income | ¥1587.7B | ¥1366.5B | +16.2% |
| Profit Before Tax | ¥1602.0B | ¥1358.3B | +17.9% |
| Net Income | ¥1154.2B | ¥972.3B | +18.7% |
| ROE | 6.1% | 4.8% | - |
For the quarter ended March 2026 (Q1), Revenue was ¥3217.5B (YoY +¥332.9B +11.5%), Operating Income was ¥1587.7B (YoY +¥221.1B +16.2%), Ordinary Income was ¥1587.3B (YoY +¥222.5B +16.3%), and Net Income was ¥1154.2B (YoY +¥181.8B +18.7%), delivering double-digit top-line and bottom-line growth. Expansion of overseas operations (notably royalties to Roche and export sales) and an improved high-margin product mix were the main drivers; Gross Profit Margin improved to 71.2% (from 69.6% +1.6pt) and Operating Margin expanded to 49.3% (from 47.4% +1.9pt), materially enhancing profitability. Operating Cash Flow (OCF) was ¥1220.4B (YoY +83.0%) and Free Cash Flow was ¥2358.4B, ample liquidity that largely absorbed prior-period special dividend payments of ¥2419.9B, leaving cash at ¥4179.8B. Equity Ratio was 84.2%, indicating very strong financials, while continuing R&D investment of ¥418.9B (R&D-to-sales 13.0%) alongside high profit generation.
【Revenue】 Revenue of ¥3217.5B (YoY +11.5%) comprised product sales of ¥2915.8B (YoY +12.3%) and other sales revenues of ¥301.7B (YoY +5.0%). By region, Japan sales were ¥1116.0B (product ¥1114.3B, YoY +8.2%) while overseas sales were ¥2101.5B (product ¥1801.5B, YoY +14.9%), driving strong growth. Within overseas, Switzerland (mainly royalties to Roche and exports) accounted for ¥1994.2B (YoY +13.2%), representing 62.0% of total; sales to key customer Roche were ¥1857.1B (YoY +9.0%), and sales to Alfressa were ¥372.5B (YoY +23.7%). Growth drivers included steady demand for existing products plus rising royalty income and export growth, which improved product mix. Cost of sales ratio improved to 28.8% (from 30.4% -1.6pt), securing a gross margin of 71.2%, aided by a higher share of high-value-added products and scale effects.
【Profitability】 Operating Income was ¥1587.7B (YoY +16.2%), with an Operating Margin of 49.3% (from 47.4% +1.9pt). Gross profit was ¥2289.6B (+14.2%). R&D expenses were ¥418.9B (R&D-to-sales 13.0%, YoY +2.3%), a modest increase, while SG&A was ¥289.0B (YoY +24.4%) which accelerated somewhat; however, significant gross margin improvement drove Operating Income growth outpacing Revenue growth. Other operating income (expense) was net income of ¥0.6B (prior ¥0.18B), a slight improvement. Ordinary Income was ¥1587.3B (YoY +16.3%), with financial income of ¥0.4B (prior ¥0.03B) and other financial items of ¥13.9B (prior -¥8.3B) turning financials slightly positive. Profit Before Tax was ¥1602.0B (YoY +17.9%); after corporate taxes and others of ¥447.8B (effective tax rate 28.0%, slightly down from 28.4%), quarterly Net Income was ¥1154.2B (YoY +18.7%), achieving double-digit profit growth. Comprehensive income was ¥1237.2B (YoY +24.6%), with Cash Flow Hedges +¥81.7B and Foreign Currency Translation +¥2.5B contributing to Other Comprehensive Income of ¥83.1B (prior +¥20.4B). In conclusion, expansion of overseas products and a higher-margin mix drove revenue and profit growth, improving both quality and quantity of profitability.
The Group operates a single pharmaceuticals business and does not have multiple reportable segments; therefore, segmental operating profit analysis is not applicable.
【Profitability】Operating Margin 49.3% improved +1.9pt from 47.4%, supported by Gross Margin 71.2% (from 69.6% +1.6pt) and controlled SG&A ratio of 9.0%. Net Margin 35.9% (from 33.7% +2.2pt); ROE 6.1% is appropriate relative to Equity of ¥19077.2B, but Total Asset Turnover 0.14x/year is low, indicating room to improve asset efficiency. R&D ratio 13.0% (from 14.2% -1.2pt) is somewhat reduced and warrants attention for medium-to-long-term competitiveness. 【Cash Quality】OCF ¥1220.4B equals 1.06x Net Income ¥1154.2B, indicating good quality; subtotal before working capital changes was ¥2113.4B, with corporate tax payments of ¥893.0B and working capital adjustments generating Free Cash Flow ¥2358.4B. 【Investment Efficiency】Capex ¥126.6B and intangible asset acquisitions ¥78.6B show continued development investment; net proceeds from sale of securities (sales ¥3814.5B - purchases ¥2604.7B) resulted in Investment Cash Flow inflow of ¥1138.0B. Total assets ¥22651.0B decreased ¥2035.0B from prior fiscal year-end, primarily due to compression of current assets to ¥15394.4B (securities -¥1209.8B, receivables -¥901.3B). 【Financial Soundness】Equity Ratio 84.2% and effectively zero interest-bearing debt indicate very strong finances; Current Ratio 470% (Current Assets ¥15394.4B / Current Liabilities ¥3277.0B) shows ample short-term liquidity. Cash and cash equivalents ¥4179.8B represent 18.5% of total assets, maintaining high liquidity on hand.
OCF was ¥1220.4B (YoY +83.0%), derived from subtotal ¥2113.4B less corporate tax payments ¥893.0B, defined contribution payments ¥5.3B, provisions payments ¥6.0B, and other working capital changes -¥151.3B. Working capital provided ¥566.6B of cash inflow during the period, aided by accounts receivable reduction of ¥901.3B and net proceeds from sale of securities, while inventories increased ¥114.4B, revealing inventory holding risk. Investment Cash Flow was a large inflow of ¥1138.0B, with securities sales ¥3814.5B far exceeding capex ¥126.6B and intangible asset acquisitions ¥78.6B; proceeds from sale of investment securities ¥118.5B also contributed. Financing Cash Flow was a ¥2445.8B outflow, driven mainly by parent company dividend payments ¥2419.9B (2.6x prior year ¥934.1B, including a commemorative dividend), lease liability payments ¥25.1B and interest payments ¥1.4B. Free Cash Flow ¥2358.4B almost covered dividend payments; after FX effects +¥1.3B, cash decreased slightly by ¥8.62B, leaving ending cash ¥4179.8B and maintaining ample liquidity. OCF/Net Income 1.06x is in a high-quality range; although some concerns exist around working capital efficiency, overall cash-generation capacity is strong.
Quarterly Net Income ¥1154.2B versus Comprehensive Income ¥1237.2B shows a difference of +¥83.1B, primarily from Cash Flow Hedges +¥81.7B (FX hedge valuation gains) and Foreign Currency Translation +¥2.5B. Operating Income ¥1587.7B is composed of recurring business earnings; Other Operating Income (Expense) +¥0.6B is minor and indicates limited one-off factors. Financial income ¥0.4B and financial expenses are negligible; Other Financial items +¥13.9B (from -¥8.3B prior) include securities valuation gains and FX effects but are small in scale. OCF subtotal ¥2113.4B significantly exceeds Operating Income ¥1587.7B due to additions for non-cash expenses such as depreciation, deferred taxes, and share-based compensation. Working capital change provided +¥566.6B of cash inflow, but inventory increase of ¥114.4B likely reflects build-up for production plans and demand expectations and should be monitored for prolonged buildup in the next quarter. Accounts receivable decline -¥901.3B may reflect timing corrections and suggests shortened receivables collection period. Corporate tax payments ¥893.0B represent 55.7% of Profit Before Tax ¥1602.0B, indicating appropriate tax cash flows. Overall, most profits are generated from recurring operations and earnings quality is high, though there are signs of structural issues in working capital efficiency that warrant attention.
No full-year guidance has been disclosed; therefore progress analysis is not applicable. There is no revision to the Q1 dividend forecast, and full-year dividend forecast remains ¥66 (ordinary dividend) unchanged.
Dividend payments in Q1 were ¥2419.9B (parent company shareholders), approximately 2.6x the prior period ¥934.1B. The prior fiscal year included a 100th-anniversary commemorative dividend of ¥150, making the annual dividend ¥272 (ordinary ¥122 + commemorative ¥150); the Q1 payment reflects timing effects for the second-quarter and year-end distributions. Full-year dividend forecast is ¥66, returning to normal levels after the prior commemorative dividend. Against Q1 Net Income ¥1154.2B, dividend payments ¥2419.9B temporarily push the Payout Ratio above 200%, but this is due to timing of prior-period year-end payments and will normalize on an annual basis. Changes in treasury shares were minor at -¥0.2B, with share-based compensation transactions ¥0.95B and stock option exercises ¥0.62B being small. The majority of total shareholder returns are dividends; no share buybacks were executed. Free Cash Flow ¥2358.4B largely covered dividend payments, and with cash ¥4179.8B and Equity Ratio 84.2% the sustainability of dividends is high. Dividend policy centers on ordinary dividends, and the company appears to revert to normal mode after the commemorative dividend.
Customer Concentration Risk: Sales to major customer Roche of ¥1857.1B account for 57.7% of total; any contract changes or reduction in transactions with Roche would directly impact performance. Although YoY +9.0% and currently healthy, the high concentration remains a principal source of revenue volatility, and portfolio diversification is a challenge.
Deterioration of Working Capital Efficiency: Inventories ¥2882.9B increased 4.1% YoY; year-end inventory build-up is presumed to be for production planning and demand response, but if prolonged it would heighten capital tie-up and obsolescence risk. Trade receivables ¥3527.5B decreased -20.3% showing temporary improvement, but given historically high DSO levels structural improvement in collection cycles should be monitored.
Drug Price Revisions & FX Risk: Domestic and international drug price revisions or reductions in insurance reimbursement prices directly pressure Revenue and gross margins. FX movements (CHF, USD) affect yen-converted royalty and export sales to Roche; Cash Flow Hedges partially mitigate this but FX remains a major source of earnings volatility. Last period FX translation contributed +¥2.5B, but future yen appreciation could be a headwind.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 49.3% | – | – |
| Net Margin | 35.9% | – | – |
Industry benchmark data are limited, so only the company’s absolute levels are shown. Operating Margin 49.3% and Net Margin 35.9% are estimated to be high within the pharmaceuticals industry.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 11.5% | – | – |
Revenue Growth 11.5% maintains double-digit growth and rates highly among major domestic pharmaceutical companies.
※ Source: Company aggregation
Sustainability of High Gross Margin & High Operating Margin: Gross Margin 71.2% and Operating Margin 49.3% are extremely high, driven primarily by royalties to Roche and expansion of high-value-added products. Maintenance of product mix (competitiveness of existing products and new drug launches), drug price revisions, and FX trends will be key to sustaining gross margins. SG&A ratio 9.0% is efficient but the YoY +24.4% acceleration warrants monitoring of cost discipline in subsequent quarters.
Strong Cash Generation and Flexibility in Capital Allocation: Free Cash Flow ¥2358.4B nearly covered dividends ¥2419.9B, and robust cash ¥4179.8B with Equity Ratio 84.2% provides high flexibility in capital allocation. R&D investment at 13.0% (down from 14.2% prior) has slightly declined and merits monitoring for pipeline competitiveness over the medium to long term. Net proceeds from sale of securities made Investment Cash Flow substantially positive, but this is interpreted as temporary liquidity optimization; trends in sustained capex and development spending should be verified in upcoming quarters.
Monitoring Working Capital Efficiency and Customer Concentration: Inventory increase of ¥114.4B signals potential inventory aging risk, while accounts receivable reduction of -¥901.3B is a one-time improvement; given historically high DSO levels, sustainability of structural improvement should be confirmed. High Roche share at 57.7% remains a primary source of earnings volatility, and changes in Roche contracts, FX, or Roche strategy would directly affect performance. Watch working capital ratios and progress on customer diversification in coming quarters.
This report was automatically generated by AI analyzing XBRL financial statement data. It is not a recommendation to invest in any specific security. Industry benchmarks are company-compiled reference information based on public financial statements. Investment decisions are your responsibility; consult a professional advisor as needed.